Dr. Rana McKay

You know, you have patients, they come into clinic, they're on 24 months of ADT and first visit, they're up two pounds, up two pounds, up two pounds in a year, they've gained 10 pounds and now they've got some, you know, pre-diabetes. And so, you know, The propensity for that to happen with somebody just being on therapy for six months is not as high as, you know, two years of therapy.

You know, you have patients, they come into clinic, they're on 24 months of ADT and first visit, they're up two pounds, up two pounds, up two pounds in a year, they've gained 10 pounds and now they've got some, you know, pre-diabetes. And so, you know, The propensity for that to happen with somebody just being on therapy for six months is not as high as, you know, two years of therapy.

And so I do think that the counseling is important, especially for people that are doing longer course treatment.

And so I do think that the counseling is important, especially for people that are doing longer course treatment.

And so I do think that the counseling is important, especially for people that are doing longer course treatment.

I mean, like I said, DEXA scan for select individuals, depending on duration of therapy, making sure they're up to date with their lipid panel, making sure they've had a hemoglobin A1C, if you've looked at their fasting glucose, and somebody is tracking that, you know, some patients may warrant, you know, being on a statin or being on an aspirin if they're high risk when they go on ADT.

I mean, like I said, DEXA scan for select individuals, depending on duration of therapy, making sure they're up to date with their lipid panel, making sure they've had a hemoglobin A1C, if you've looked at their fasting glucose, and somebody is tracking that, you know, some patients may warrant, you know, being on a statin or being on an aspirin if they're high risk when they go on ADT.

I mean, like I said, DEXA scan for select individuals, depending on duration of therapy, making sure they're up to date with their lipid panel, making sure they've had a hemoglobin A1C, if you've looked at their fasting glucose, and somebody is tracking that, you know, some patients may warrant, you know, being on a statin or being on an aspirin if they're high risk when they go on ADT.

And so I think making sure that that's evaluated. You know, some of these therapies can cause high blood pressure, so monitoring against that. But I think with regards to testing, for me, it's basically a hemoglobin A1c, glucose level, you know, lipid panel. You know, there's been some recent enthusiasm around coronary calcium scores with regards to CV risk.

And so I think making sure that that's evaluated. You know, some of these therapies can cause high blood pressure, so monitoring against that. But I think with regards to testing, for me, it's basically a hemoglobin A1c, glucose level, you know, lipid panel. You know, there's been some recent enthusiasm around coronary calcium scores with regards to CV risk.

And so I think making sure that that's evaluated. You know, some of these therapies can cause high blood pressure, so monitoring against that. But I think with regards to testing, for me, it's basically a hemoglobin A1c, glucose level, you know, lipid panel. You know, there's been some recent enthusiasm around coronary calcium scores with regards to CV risk.

I don't know that that's been consistently implemented across oncologic practices, but I think the education is really key.

I don't know that that's been consistently implemented across oncologic practices, but I think the education is really key.

I don't know that that's been consistently implemented across oncologic practices, but I think the education is really key.

On treatment?

On treatment?

On treatment?

Undetectable. You know, hope to get it down low. And then, you know, patients always ask me this question. Well, what about if we get it down to a certain level and whatever? And I'm like, everything that we do is to drive the levels even lower. And what we measure in the blood is like not even what is measured in the tumor.

Undetectable. You know, hope to get it down low. And then, you know, patients always ask me this question. Well, what about if we get it down to a certain level and whatever? And I'm like, everything that we do is to drive the levels even lower. And what we measure in the blood is like not even what is measured in the tumor.

Undetectable. You know, hope to get it down low. And then, you know, patients always ask me this question. Well, what about if we get it down to a certain level and whatever? And I'm like, everything that we do is to drive the levels even lower. And what we measure in the blood is like not even what is measured in the tumor.